Table 1 Results of multivariable analysis for risk factors of sentinel lymph node nonvisualization on lymphoscintigraphy after initial injection of the radiotracer

Age (years)

 < 0.001^b

 < 50

364

57 (15.7)

1

50–70

867

216 (24.9)

1.25 (0.85–1.82)

 ≥ 70

300

112 (37.3)

2.27 (1.46–3.53)

BMI (kg/m²)

0.003^b

 < 25

363

83 (22.9)

1

25–30

313

91 (29.1)

1.24 (0.87–1.77)

 ≥ 30

284

95 (33.5)

1.48 (1.04–2.12)

Unknown

571

Tumor palpability

 < 0.001^a

Palpable

938

199 (21.2)

1

Nonpalpable

593

186 (31.4)

1.54 (1.15–2.07)

Tumor location

0.591^a

Medial/central

418

108 (25.8)

Lateral

803

219 (27.3)

Unknown

310

Brand radiopharmaceutical

0.182^a

Nanocoll

1225

299 (24.4)

Nanoscan

306

86 (28.1)

Injected dose (MBq)

0.172^b

 < 100

6

1 (16.7)

100–150

1446

370 (25.6)

 ≥ 150

79

14 (17.7)

Injected volume (ml)

0.475^b

 < 0.2

409

107 (26.2)

0.2–0.3

1075

268 (24.9)

 ≥ 0.3

47

10 (21.3)

Experience of preparer (preparations)

0.390^a

 < 50

621

149 (24.0)

 ≥ 50

910

236 (25.9)

Experience of administrator (procedures)

0.739^a

 < 50

297

88 (29.6)

 ≥ 50

470

134 (28.5)

Unknown

764